2. Infection

Infection

Infection

Related Products

PDF 70.44 MB

Infection is a pathophysiological process that involves the invasion and colonization of a living organism (host) by disease-causing infectious agents, the reaction of host tissues to these agents and the toxins they produce, and the transmission of infectious agents to other hosts. Common infectious agents include viruses, viroids, prions, bacteria, nematodes, arthropods, and other macroparasites such as tapeworms. Hosts can fight infections using their immune system. Mammals often engage both innate and adaptive immune systems to eliminate infectious agents or inhibit their growth and transmission. When infection occurs, anti-infective drugs can suppress the infection. Several broad types of anti-infective drugs exist, depending on the type of organism targeted; they include antibacterial (antibiotic), antiviral, antifungal and antiparasitic agents.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-184077
    IDO1-IN-35 2701898-79-3 98%
    IDO1-IN-35 is an inhibitor of the IDO1 mutant IDO1F164A. IDO1-IN-35 inhibits the IDO1-mediated conversion of L-tryptophan to N-formyl-L-kynurenine. IDO1-IN-35 can be used in studies of viral and bacterial infections.
    IDO1-IN-35
  • HY-184146
    AD05
    AD05 is a SARS-CoV-2 main protease (Mpro) inhibitor with an IC50 of 306.5 nM. AD05 exhibits antiviral activity against wild-type SARS-CoV-2 in host cells without inducing significant cytotoxicity. AD05 can be used in studies related to SARS-CoV-2 infection.
    AD05
  • HY-184147
    AD06
    AD06 is a SARS-CoV-2 main protease (Mpro) inhibitor with an IC50 of 163.3 nM. AD06 undergoes nucleophilic attack by deprotonated Cys145, thereby blocking viral replication. AD06 inhibits the activity of wild-type SARS-CoV-2 and shows no significant cytotoxicity in mammalian cells. AD06 can be used in studies related to SARS-CoV-2 infection.
    AD06
  • HY-184156
    WSL017
    WSL017 is a cytochrome bd oxidase inhibitor with antibacterial activity against Mycobacterium tuberculosis. WSL017 can be used for the research of tuberculosis.
    WSL017
  • HY-184165
    F2F-202
    F2F-202 is a selective HDAC6 inhibitor with an IC50 of 7.1 nM, exhibiting high selectivity toward HDAC1. F2F-202 does not directly bind to or inhibit the Hda1 protease activity of Candida albicans itself, but reduces the mRNA transcription level of the Hda1 gene. When combined with Voriconazole (HY-76200), F2F-202 decreases the yeast-hypha transition rate of azole-resistant Candida albicans and impairs the antioxidant response of azole-resistant Candida albicans. F2F-202 can be used in studies related to azole-resistant Candida albicans infections.
    F2F-202
  • HY-184171
    mCMX110 2883773-06-4
    mCMX110 is an orally active SARS-CoV-2 main protease inhibitor with an IC50 of 35 nM. mCMX110 inhibits SARS-CoV-2 infection. SARS-CoV-2 mCMX110 can be used for the research of SARS-CoV-2 infection.
    mCMX110
  • HY-184181
    Antimalarial agent 63 1596337-67-5
    Antimalarial agent 63 is an inhibitor of Plasmodium falciparum. Antimalarial agent 63 exhibits inhibitory activity against field isolates of Plasmodium falciparum and Plasmodium vivax. Antimalarial agent 63 shows an antagonistic interaction when used in combination with Proguanil (HY-B0806) against Plasmodium falciparum. Antimalarial agent 63 has low cytotoxicity to hepatocytes and a high selectivity index. Antimalarial agent 63 can be used in the research of malaria.
    Antimalarial agent 63
  • HY-184182
    Antimalarial agent 64 2770244-63-6
    Antimalarial agent 64 is an orally active acridine-based antimalarial derivative and also a rapid-acting inhibitor of hemozoin formation. Antimalarial agent 64 exhibits nanomolar inhibitory activity against field isolates of Plasmodium falciparum and Plasmodium vivax. Antimalarial agent 64 localizes near the digestive vacuole of Plasmodium. Antimalarial agent 64 can be used for the research of malaria.
    Antimalarial agent 64
  • HY-184201
    Anti-MRSA agent 44 3123310-71-1 98%
    Anti-MRSA agent 44 is a potent anti-methicillin-resistant Staphylococcus aureus (MRSA) agent. Anti-MRSA agent 44 exihibits antibiofilm activity against MRSA. Anti-MRSA agent 44 reduces bacterial counts and biofilm burdens, accelerates wound healing, lowers inflammatory cytokine levels in mouse models. Anti-MRSA agent 44 can be used for the research of MRSA skin wound infection and MRSA catheter-associated biofilm infection.
    Anti-MRSA agent 44
  • HY-184202
    Antitrypanosomal agent 33 98%
    Antitrypanosomal agent 33 is a potent antitrypanosomal agent with activity against Trypanosoma cruzi intracellular amastigotes, Trypanosoma brucei brucei, and Trypanosoma brucei rhodesiense. Antitrypanosomal agent 33 can be used for the research of trypanosomiasis, chagas disease.
    Antitrypanosomal agent 33
  • HY-184205
    LASSBio-1736 1554691-37-0
    LASSBio-1736 is a Cysteine protease inhibitor and antimalarial agent. LASSBio-1736 targets the promastigote form of Leishmania major. LASSBio-1736 can be used in the research of leishmaniasis.
    LASSBio-1736
  • HY-184209
    Antifungal agent-163
    Antifungal agent-163 is an antifungal agent. Antifungal agent-163 inhibits the activity of coenzyme Q-cytochrome C reductase (CoQ-Ccr), thereby disrupting electron transport in the mitochondrial respiratory chain. Antifungal agent-163 induces intracellular ROS accumulation, causes cell membrane damage, and impairs mitochondrial function in *Sublineola* cells. Antifungal agent-163 exhibits control effects against fungal plant diseases. Antifungal agent-163 can be used in the research of sorghum anthracnose.
    Antifungal agent-163
  • HY-184214
    Antileishmanial agent-44
    Antileishmanial agent-44 is a histone deacetylase inhibitor targeting Leishmania donovani Sir2, with an IC50 of 0.652 μM against amastigotes. Antileishmanial agent-44 elevates ROS levels to induce oxidative stress, which causes mitochondrial membrane potential depolarization, cytochrome c release, phosphatidylserine externalization and DNA fragmentation, triggers apoptosis-like cell death, and arrests the cell cycle. Antileishmanial agent-44 upregulates the expression of Th1-type cytokines and NO in macrophages, reshapes host immune responses to eliminate intracellular parasites. Antileishmanial agent-44 inhibits parasites in infected golden hamsters in vivo. Antileishmanial agent-44 can be used for the research of visceral leishmaniasis.
    Antileishmanial agent-44
  • HY-184226
    ASAP-0031651
    ASAP-0031651 is an orally active inhibitor of Zika virus NS2B-NS3 protease. ASAP-0031651 binds the active site of virus NS2B-NS3 protease to inhibit its function. ASAP-0031651 exerts antiviral activity against Zika virus. ASAP-0031651 can be used for the research of virus infection.
    ASAP-0031651
  • HY-184237
    Antibacterial agent 349
    Antibacterial agent 349 is an antibacterial agent. Antibacterial agent 349 impairs reactive oxygen species clearance, disrupts citrate cycle homeostasis and induces metabolic stress. Antibacterial agent 349 compromises bacterial membrane integrity, increases permeability, and causes intracellular component leakage. Antibacterial agent 349 can be used for the research of bacterial leaf streak.
    Antibacterial agent 349
  • HY-184248
    FM-74-103
    FM-74-103 is a selective GSPT1 PROTAC degrader and broad-spectrum antiviral agent. FM-74-103 recruits GSPT1 to the Cereblon E3 ligase to form a ternary complex, thereby driving GSPT1 ubiquitination and proteasomal degradation. FM-74-103 inhibits the replication of IAV, SARS-CoV-2 and CMV (including Nucleozin (HY-50001)-resistant influenza A virus). FM-74-103 can be used in research related to influenza A virus infection, SARS-CoV-2 infection and cytomegalovirus infection.
    FM-74-103
  • HY-184325
    NDM-622
    NDM-622 is a Colistin (HY-113678) adjuvant. NDM-622 weakly inhibits IKKβ with an IC50 of 20.40 μM. NDM-622 reduces the minimum inhibitory concentration of colistin against colistin-highly-resistant Acinetobacter baumannii and Klebsiella pneumoniae. NDM-622 decreases bacterial colony-forming units in a mouse peritonitis model infected with colistin-highly-resistant Klebsiella pneumoniae. NDM-622 does not modify bacterial lipid A, induce reactive oxygen species production, or increase bacterial membrane permeability. NDM-622 can be used in the research of extensively drug-resistant Gram-negative bacterial infections, colistin-resistant Acinetobacter baumannii infections, and Klebsiella pneumoniae infections.
    NDM-622
  • HY-184345
    (+)-Cyclozonarone 332858-46-5 98%
    (+)-Cyclozonarone is a benzoquinone derivative found in brown algae Dictyopteris undulata, with activity against T. cruzi epimastigotes, Tulahuen strains. (+)-Cyclozonarone inhibits growth of cancer and endothelial cells, and exhibits anti-leishmanial activity. (+)-Cyclozonarone can be used for the research of lung carcinoma, colon carcinoma, prostate carcinoma.
    (+)-Cyclozonarone
  • HY-185123
    Pig TRIM56 mRNA
    Pig TRIM56 mRNA encodes the pig TRIM56 protein, an interferon-stimulated gene (ISG) that acts as an important innate immune factor. Overexpression of TRIM56 restricts viral replication by enhancing TLR3-TRAF3-mediated IFN-β production.
    Pig TRIM56 mRNA
  • HY-185183
    DTriP-22 717098-99-2
    DTriP-22 is a highly potent and low-toxicity inhibitor of enterovirus 71 3D polymerase (EV71 3D polymerase). DTriP-22 exhibits broad-spectrum anti-RNA virus activity (particularly against picornaviruses) beyond EV71, but shows no activity against DNA viruses. DTriP-22 acts at the early stage of viral replication and exerts its function by specifically inhibiting viral RNA synthesis. DTriP-22 can be used in anti-enterovirus research.
    DTriP-22
Cat. No. Product Name / Synonyms Application Reactivity